An observational study in Cataract, Vitreous Hemorrhage and Retinal Detachment, sponsored by Alcon Research. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Alcon Research (part of Alcon) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Cataract by Alcon — 4 open to participants now, 6 under way, none of them phase 3. Cataract · Alcon.
Among the 116 studies in Cataract by Alcon, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2026, is one of 12 observational ones, and was the 113th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →4 of the 116 studies in Cataract by Alcon are open now, in 6 countries. Recruiting first, the newest first:
Alcon Research · Sites in Australia, India, Philippines
Ages 22+
Alcon Research · Sites in United States
Ages 22+
Alcon Research · Sites in United States, India, Philippines and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 90 across 476 observational studies indexed under Cataract.
Median enrollment 95 across the 104 interventional studies, 145 across the 12 observational. Of the 101 that completed or were terminated, 76 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
4 of the studies in Cataract by Alcon that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05317728Alcon ResearchClinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design | 2026-11 |
| NCT06987474Alcon ResearchCapella Scientia Development Study | 2027-05 |
| NCT07228091Alcon ResearchSurgical Procedure Efficiency Evaluation stuDy | 2027-06 |
| NCT07587138Alcon ResearchClinical Evaluation of a Novel Trifocal IOL | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 116 studies in Cataract by Alcon, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this real-world evidence study is to compare surgical procedure times for UNITY® VCS and CONSTELLATION® Vision System.
Eligible subjects will undergo routine scheduled combined anterior-posterior segments surgery (phacovitrectomy). This single visit, time-and-motion study will be conducted in the United Kingdom. This study will be conducted by Alcon Vision LLC.
Subjects will be recruited from the clinical practice of the participating Investigator.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will undergo routine scheduled combined anterior-posterior segments surgery (phacovitrectomy)
Device: UNITY VCS
Subjects will undergo routine scheduled combined anterior-posterior segments surgery (phacovitrectomy)
Device: CONSTELLATION
UNITY® VCS is a CE-marked, FDA-approved ophthalmic microsurgical system that is indicated for both anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The focus of this study will be on combined anterior-posterior segments surgery (phacovitrectomy).
Also known as: UNITY® Vitreoretinal Cataract System (VCS)
CONSTELLATION is a CE-marked, FDA-approved ophthalmic microsurgical system that is indicated for both anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The focus of this study will be on combined anterior-posterior segments surgery (phacovitrectomy).
Also known as: CONSTELLATION® Vision System
Proportion of surgeons replying "efficient" or "very efficient" to the question, "How would you rate overall OR (operating room) efficiency of the console for the combined phaco-vitrectomy surgery (including set-up/tear-down)?
Responses will be collected on a 5-point scale where 1=Very Inefficient, 2=Inefficient, 3=Neutral, 4=Efficient, and 5=Very Efficient.
Time frame: Up to Day 1 post completion of the surgery
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.
Of 67 industry-sponsored observational studies under Cataract, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 16 months is above that.
Counting every sponsor, half of 235 studies reached it within 16 months; a quarter within 9 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Mar 2027 → Jun 2027 and completion Mar 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.